source
- Abbott Beats Q2 Expectations with Strong Device and Diagnostic Sales, Raises Profit ForecastAbbott reported second‑quarter results that exceeded analysts' forecasts, easing concerns about potential impact of ACA subsidy cuts on medtech firms. Diagnostics revenue jumped 42% year‑over‑year…
- BlossomHill and Latigo lead a surge of biotech IPOs after summer dry spellAfter a seven‑month lull that left no biotech companies on the public markets last summer, the sector is seeing renewed activity. BlossomHill Therapeutics and Latigo have filed to list on Nasdaq,…